In old, obese mice, the weight-loss drug semaglutide took more muscle than in young ones

Old female mice given semaglutide lost noticeably more leg muscle than earlier studies had found in young mice, and old males lost some muscle strength. It is a small three-week study in mice, not yet peer-reviewed, and says nothing yet about what happens in older people.

Drugs such as semaglutide have changed the treatment of obesity. They mimic GLP-1, a gut hormone that signals fullness, and people taking them often lose a large share of their body weight. But part of the weight lost is lean mass, everything that isn't fat, and that has raised a worry: are people also losing muscle? For older adults, who already lose muscle with age (sarcopenia), that would be a real concern.

A team at the University of Utah had earlier found that in young obese mice, semaglutide did not cost much muscle. Now they repeated the experiment in old mice. Here the picture looked worse: old females lost more leg muscle, and old males lost some strength in one muscle. The study is a preprint (not yet peer-reviewed), was done in mice, and lasted only three weeks.

What they did

The team bought 17-month-old mice (the authors compare 18- to 21-month-old mice to people in their sixties) and fed them a high-fat diet for 12 weeks to make them obese. At 21 months, the mice received a daily injection of semaglutide at a low or a high dose, or a placebo, for three weeks while staying on the fatty diet. A group of lean mice of the same age, kept on normal food, served as a reference. Each group had between 5 and 10 mice.

The team tracked body weight and food intake, measured fat and lean mass with a scanner, then weighed individual muscles and organs. They also tested how much force two small leg muscles could produce when stimulated with electricity in the lab, and looked at muscle fibres under the microscope.

What they found

  • Weight loss depended on the dose. Males lost 11.3% (low dose) and 20.2% (high dose) of their body weight; females lost 21.1% and 26.1%. Most of it came in the first week, and food intake was back to normal by the second week.
  • Fat loss was similar in both sexes and matched that seen in young mice.
  • Lean mass fell more in females (8.6% and 8.3%) than in males (2.3% and 6.6%). Overall, the old mice actually lost less lean mass than young mice in earlier studies.
  • But in old females, more of that loss was muscle. At the high dose, the quadriceps (the big thigh muscle) was 14.2% lighter and the calf muscle 9.4% lighter than in placebo mice, losses larger than the drop in lean mass as a whole. Muscle fibres were also thinner. In young mice, by contrast, much of the lean mass lost had come from organs such as the liver.
  • In males, muscle weight was largely spared, apart from a trend towards a smaller soleus, a calf muscle. However, the high dose reduced the maximum force of one fast leg muscle by 19.2%, even though that muscle had not shrunk. Muscle force in females was not affected.
  • No reserve to lose. In young mice, the fatty diet had first made muscles bigger and stronger, so semaglutide only brought them back to the level of lean mice. In old mice, the diet had not built extra muscle, so the treated mice ended up below lean mice of the same age.

What to keep in mind

  • Mice are not people. The authors themselves stress the limits of translating mouse results and call for clinical studies. The doses were chosen to give weight loss in mice comparable to that of the highest approved human dose, but that comparison is rough.
  • Small groups and a short treatment: 5 to 10 mice per group, for three weeks. Long-term use, and whether muscle recovers, were not studied.
  • Results differed by sex in ways that aren't explained: females lost muscle mass, males lost strength. Neither was tested for mechanism.
  • Not yet peer-reviewed.
  • The mice were not old enough to have sarcopenia; in this strain it begins at around 26 to 28 months, so the results may not apply to frailer animals, or people.

Why it matters

Semaglutide and similar drugs are prescription medicines with known side effects, and they are increasingly prescribed to older adults. Whether the lean mass they lose is real, functional muscle is still an open question; the authors note that no published human study has yet measured it with gold-standard methods. This mouse study suggests that age and sex could change the answer, and that earlier reassuring results in young animals may not carry over to old ones. The authors argue that ongoing human trials should include older adults, especially those at risk of muscle loss, and measure muscle mass and strength directly.